CA2909234C - Extracts and preparation thereof from inflamed skins of rabbits inoculated with vaccinia virus - Google Patents

Extracts and preparation thereof from inflamed skins of rabbits inoculated with vaccinia virus Download PDF

Info

Publication number
CA2909234C
CA2909234C CA2909234A CA2909234A CA2909234C CA 2909234 C CA2909234 C CA 2909234C CA 2909234 A CA2909234 A CA 2909234A CA 2909234 A CA2909234 A CA 2909234A CA 2909234 C CA2909234 C CA 2909234C
Authority
CA
Canada
Prior art keywords
extract
preparation
vaccinia virus
sulfated tyrosine
tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2909234A
Other languages
English (en)
French (fr)
Other versions
CA2909234A1 (en
Inventor
Yoshitaka Nakazawa
Yoji Shibayama
Ko Nakamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Publication of CA2909234A1 publication Critical patent/CA2909234A1/en
Application granted granted Critical
Publication of CA2909234C publication Critical patent/CA2909234C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2909234A 2013-04-30 2014-04-30 Extracts and preparation thereof from inflamed skins of rabbits inoculated with vaccinia virus Active CA2909234C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-095565 2013-04-30
JP2013095565 2013-04-30
PCT/JP2014/061959 WO2014178394A1 (ja) 2013-04-30 2014-04-30 抽出物及び該抽出物を含有する製剤

Publications (2)

Publication Number Publication Date
CA2909234A1 CA2909234A1 (en) 2014-11-06
CA2909234C true CA2909234C (en) 2023-03-14

Family

ID=51843519

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909234A Active CA2909234C (en) 2013-04-30 2014-04-30 Extracts and preparation thereof from inflamed skins of rabbits inoculated with vaccinia virus

Country Status (9)

Country Link
US (1) US9884077B2 (https=)
EP (1) EP2992889B1 (https=)
JP (3) JP6469002B2 (https=)
KR (1) KR102182240B1 (https=)
CN (3) CN115629169A (https=)
AU (1) AU2014260736B2 (https=)
CA (1) CA2909234C (https=)
TW (2) TWI737229B (https=)
WO (1) WO2014178394A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103357006B (zh) 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
WO2014178394A1 (ja) * 2013-04-30 2014-11-06 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
TWI711456B (zh) * 2015-05-29 2020-12-01 日商日本臟器製藥股份有限公司 牛痘病毒接種炎症組織萃取物及其用途以及其判定或評估方法
AU2018394182B2 (en) * 2017-12-28 2024-08-08 Hyogo College Of Medicine Lipocalin-type prostaglandin D2 synthase production accelerating agent
CN113267574A (zh) * 2020-02-17 2021-08-17 上海交通大学医学院附属瑞金医院 O-硫化酪氨酸的检测方法及其用途

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB697351A (en) 1951-01-16 1953-09-23 Masuichi Takino Improved process for the manufacture of nerve sedatives
JPS53101515A (en) 1977-02-17 1978-09-05 Nippon Zoki Pharmaceutical Co Medicine having anodyne * sedative and antiallergic activity and production thereof
JPS5587724A (en) 1978-12-27 1980-07-02 Nippon Zoki Pharmaceut Co Ltd Selective immune enhancer
JPS5777697A (en) 1980-11-04 1982-05-15 Nippon Zoki Pharmaceut Co Ltd Physiologically active substance nsq
JPS5835117A (ja) 1981-08-25 1983-03-01 Nippon Zoki Pharmaceut Co Ltd 新規生理活性物質ｎｓｈ
JP2651674B2 (ja) 1987-07-23 1997-09-10 日本臓器製薬 株式会社 新規生理活性物質及びその製造方法
JPS6479657A (en) 1987-09-22 1989-03-24 Nippon Zoki Pharmaceutical Co Vital decision of medicine
US4985254A (en) 1987-11-06 1991-01-15 Nippon Zoki Pharmaceutical Co., Ltd. Method of treating ischemic diseases
JPH0825885B2 (ja) 1988-04-15 1996-03-13 日本臓器製薬株式会社 特発性血小板減少性紫斑病治療剤
ATE94401T1 (de) 1988-04-30 1993-10-15 Nippon Zoki Pharmaceutical Co Physiologisch wirkende substanzen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen davon.
JP2539665B2 (ja) 1988-06-20 1996-10-02 日本臓器製薬株式会社 神経疾患治療剤
JP2539669B2 (ja) 1988-07-15 1996-10-02 日本臓器製薬株式会社 糖尿病性神経障害治療剤
JPH06273415A (ja) * 1993-03-18 1994-09-30 Unitika Ltd コレシストキニンの測定用試薬及び測定方法
JP2594222B2 (ja) 1993-09-28 1997-03-26 日本臓器製薬株式会社 新規生理活性物質−ｋｆ
JP3852786B2 (ja) 1995-04-25 2006-12-06 日本臓器製薬株式会社 骨萎縮改善剤
JP4033936B2 (ja) 1997-01-08 2008-01-16 日本臓器製薬株式会社 一酸化窒素産生抑制剤
JPH1180005A (ja) 1997-09-12 1999-03-23 Nippon Zoki Pharmaceut Co Ltd 骨粗鬆症治療剤
JPH11139977A (ja) * 1997-11-07 1999-05-25 Nippon Zoki Pharmaceut Co Ltd Ｎｅｆ作用抑制剤
KR19990044835A (ko) 1997-11-28 1999-06-25 고니시 진우에몬 생약추출물
EP0953352A1 (en) 1998-04-27 1999-11-03 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for ischemic diseases
JP2000016942A (ja) 1998-04-27 2000-01-18 Nippon Zoki Pharmaceut Co Ltd 虚血性疾患治療剤
US6306345B1 (en) 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
CN100425692C (zh) 1998-06-02 2008-10-15 株式会社富吉摩托普拉泽兹 含有高质量生理活性的家兔发痘组织的制造方法
CN1055249C (zh) * 1998-07-15 2000-08-09 沈继平 一种镇痛药和其制造方法
JP2000336034A (ja) 1999-03-19 2000-12-05 Nippon Zoki Pharmaceut Co Ltd ケモカイン産生促進剤
EP1046397A3 (en) 1999-04-15 2003-04-23 Nippon Zoki Pharmaceutical Co. Ltd. Novel bioactivating substance
US6726932B2 (en) 2000-02-18 2004-04-27 Nippon Zoki Pharmaceutical Co., Ltd. Fatty acid-containing composition
JP2004083487A (ja) * 2002-08-27 2004-03-18 Morinaga Milk Ind Co Ltd 抗ウイルス組成物及びウイルス感染症予防・治療用組成物
CA2503810C (en) 2002-10-31 2012-03-13 Kusuki Nishioka Therapeutic agent for fibromyalgia
CN1207005C (zh) 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
JP2004300146A (ja) 2003-03-17 2004-10-28 Nippon Zoki Pharmaceut Co Ltd 感染防御剤
US7060308B2 (en) 2003-06-04 2006-06-13 Ramaswamy Rajendran Caralluma extract products and processes for making the same
JP3818657B2 (ja) 2004-12-01 2006-09-06 日本臓器製薬株式会社 乾燥物及びその製造方法
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
CN1613305B (zh) 2004-12-06 2011-01-12 威世药业（如皋）有限公司 一种从含新型活性物质的兔皮中提取的活性制剂
US20060134646A1 (en) 2004-12-17 2006-06-22 Ansari Aftab A Method for treatment of HIV infection
CN100542543C (zh) 2005-06-17 2009-09-23 日本脏器制药株式会社 干燥物及其制造法
TWI406664B (zh) 2006-03-30 2013-09-01 Univ Kyoto 硫氧還蛋白（ｔｈｉｏｒｅｄｏｘｉｎ）產生促進劑
EP2075341A4 (en) 2006-09-06 2010-09-08 Nippon Zoki Pharmaceutical Co METHOD FOR THE INVESTIGATION, DETERMINATION OR EVALUATION BY MEANS OF GENE EXPRESSION ANALYSIS
CN101790377A (zh) 2007-08-31 2010-07-28 国立大学法人九州大学 抗癌剂导致的末梢神经障碍的预防或减轻剂
TWI483729B (zh) 2010-03-11 2015-05-11 Nippon Zoki Pharmaceutical Co 慢性前列腺炎、間質性膀胱炎及／或排尿障礙之改善或治療劑
JP4899224B2 (ja) * 2010-05-11 2012-03-21 春三 小林 動脈硬化改善剤
WO2011162317A1 (ja) 2010-06-25 2011-12-29 日本臓器製薬株式会社 被検物質の判定又は評価方法
CA2808927C (en) 2010-10-14 2018-10-30 Nippon Zoki Pharmaceutical Co., Ltd. A method for promoting the synthesis of collagen and proteoglycan in chondrocytes
CN103357006B (zh) 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
WO2014178394A1 (ja) * 2013-04-30 2014-11-06 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
US9764032B2 (en) 2015-02-11 2017-09-19 Rozita Moshtagh Multi-vitamin kids gummies having baobab and method of making thereof

Also Published As

Publication number Publication date
US20160089402A1 (en) 2016-03-31
JP6680829B2 (ja) 2020-04-15
JP6943894B2 (ja) 2021-10-06
AU2014260736A1 (en) 2015-11-05
CA2909234A1 (en) 2014-11-06
EP2992889A4 (en) 2016-12-07
EP2992889A1 (en) 2016-03-09
CN115629169A (zh) 2023-01-20
KR20160002767A (ko) 2016-01-08
JP6469002B2 (ja) 2019-02-13
AU2014260736B2 (en) 2018-10-04
CN105163746A (zh) 2015-12-16
TW201521748A (zh) 2015-06-16
TW202027765A (zh) 2020-08-01
TWI737229B (zh) 2021-08-21
US9884077B2 (en) 2018-02-06
TWI687223B (zh) 2020-03-11
KR102182240B1 (ko) 2020-11-24
EP2992889B1 (en) 2019-06-19
JPWO2014178394A1 (ja) 2017-02-23
CN115629217A (zh) 2023-01-20
JP2018162252A (ja) 2018-10-18
WO2014178394A1 (ja) 2014-11-06
HK1221162A1 (en) 2017-05-26
JP2019073535A (ja) 2019-05-16

Similar Documents

Publication Publication Date Title
JP6943894B2 (ja) 抽出物及び該抽出物を含有する製剤
US11529374B2 (en) Extract and formulation including extract
JP5275502B1 (ja) 抽出物及び製剤
JP6043922B2 (ja) 抽出物及び該抽出物を含有する製剤
JP5490939B2 (ja) 抽出物及び製剤
HK1221162B (en) Extract, and preparation containing said extract
JP6412891B2 (ja) 抽出物及び製剤
JP5438234B1 (ja) 抽出物及び該抽出物を含有する製剤
JP5844320B2 (ja) 抽出物及び該抽出物を含有する製剤
JP5844338B2 (ja) 抽出物及び該抽出物を含有する製剤
HK1211496B (en) Extract and formulation including extract
JP2018162311A (ja) 抽出物及び製剤
JP2016216518A (ja) 抽出物及び該抽出物を含有する製剤
JP2014101381A (ja) 抽出物及び製剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251006

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260120